VivoSeq
Other

Lung Inflammation

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Lung Inflammation is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed5 · 71%
Recruiting2 · 29%

Clinical Trials

Trial Activity

7 trials

Macrophage Regulation of Ozone-Induced Lung Inflammation
Recruiting·—·Phase 1·NCT05773001·100 enrolled
PET Imaging CCR2 in Lung Inflammation
Recruiting·WWashington University School of Medicine·Phase 1·NCT03492762·110 enrolled
Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment
Completed·MMedical University of Vienna·N/A·NCT01714427·36 enrolled
Assessing NOS Uptake With PET Imaging in Lung Inflammation
Completed·WWashington University School of Medicine·Phase 1·NCT02151552·3 enrolled
Carbon Monoxide to Prevent Lung Inflammation
Completed·National Institutes of Health Clinical Center (CC)·Phase 1·NCT00094406·35 enrolled
Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Completed·MMichael Campos, MD·Phase 2·NCT01669421·10 enrolled
Effect of Curcumin on Lung Inflammation
Completed·—·N/A·NCT01514266·57 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)